NCT02956577

Brief Summary

The purpose of this study was to investigate the influence of micro- and macrovascular changes on the cardiac function in relation to left ventricular function and coronary arteries during one year in patients with type 2 diabetes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2016

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 16, 2016

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

October 30, 2016

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 7, 2016

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2018

Completed
Last Updated

October 22, 2018

Status Verified

October 1, 2018

Enrollment Period

2.5 years

First QC Date

October 30, 2016

Last Update Submit

October 19, 2018

Conditions

Keywords

Global Longitudinal Strain (GLS)Coronary Flow Velocity Reserve (CFVR)Cardiac dysfunctionMicrocirculationCoronary Computed Tomography Angiography (CCTA)Type 1 DiabetesType 2 Diabetes

Outcome Measures

Primary Outcomes (1)

  • Changes in Global Longitudinal Strain (GLS) stratified by Coronary Artery Calcium Score (CAC) in patients with diabetes during one year of follow-up

    To evaluate the changes in GLS stratified by CAC during one year of follow-up in patients with diabetes compared to non-diabetic subjects

    baseline, 12 months

Secondary Outcomes (9)

  • Changes in GLS stratified by Coronary Flow Velocity Reserve (CFVR) in patients with diabetes during one year of follow-up

    baseline, 12 months

  • Correlation between biomarkers and GLS stratified by CFVR

    12 months

  • Correlation between biomarkers and GLS stratified by CAC

    12 months

  • Changes in LV function stratified by CAC

    baseline, 12 months

  • Changes in LV function stratified by CFVR

    baseline, 12 months

  • +4 more secondary outcomes

Other Outcomes (9)

  • Relationship between strain values and framerate

    baseline, 12 months

  • Relationship between strain values and omitted myocardial segments

    baseline, 12 months

  • Correlation between dysglycaemia and Left Ventricle Mass (LVM)

    Baseline

  • +6 more other outcomes

Study Arms (3)

T2

Patients with type 2 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at Odense University Hospital (OUH) Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional Funen Diabetes Database (FDDB). Data on historical invasive procedures due to cardiac disease were registered in Western Denmark Heart Registry (WDHR).

T1

Patients with type 1 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at OUH Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional FDDB. Data on historical invasive procedures due to cardiac disease were registered in WDHR.

Non-diabetic subjects

Non-diabetic subjects without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were included from The Danish Cardiovascular Screening trial (DANCAVAS). A randomized controlled trial with the primary aim to evaluate the health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood pressure index (ABI) as part of a multifocal screening and intervention program for cardiovascular disease in men aged 65-74.

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with diabetes type 1+2 and non-diabetic subjects from the DANCAVAS trial (NCT00662480)

You may qualify if:

  • Ability to give informed consent
  • Estimated glomerular filtration rate (eGFR) \> 45 ml/min
  • NYHA I + II

You may not qualify if:

  • ° or 3° AV-block at baseline
  • Long QT-syndrome at baseline
  • Sinus node dysfunction with long sinus arrest at baseline
  • Angina pectoris at baseline
  • Ejection fraction (EF) \< 40% at baseline
  • Atrial fibrillation at baseline
  • Usage of dipyridamol at baseline
  • Aortic stenosis and left ventricle hypertrophia at baseline
  • Aortic insufficiency and left ventricle dilatation at baseline
  • Medication for asthma within the last 4 years prior to baseline
  • Medication for chronic obstructive pulmonary disease (COPD) at baseline
  • Allergy to contrast agent at baseline
  • Significant stenosis in left main (LM) / left anterior descending (LAD) artery at baseline
  • Not feasible to measure or perform coronary flow velocity reserve (CFVR)
  • Poor quality of echocardiographic images
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cardiovascular Research Unit, OUH Svendborg Hospital

Svendborg, 5700, Denmark

Location

Biospecimen

Retention: SAMPLES WITH DNA

Storage in biobank (-80° C): 5 x 2 ml (serum). 4 x 2 ml (ethylenediaminetetraacetic acid). 2 x 2 ml (sodium citrate) 1 x 2 ml (erythrocyte sedimentation rate)

MeSH Terms

Conditions

Ventricular Dysfunction, LeftDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Ventricular DysfunctionHeart DiseasesCardiovascular DiseasesDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Kenneth Egstrup, DMSci

    Odense University Hospital (OUH) Svendborg Hospital

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Ph.D-student

Study Record Dates

First Submitted

October 30, 2016

First Posted

November 7, 2016

Study Start

March 16, 2016

Primary Completion

September 20, 2018

Study Completion

September 20, 2018

Last Updated

October 22, 2018

Record last verified: 2018-10

Data Sharing

IPD Sharing
Will not share

Locations